A Phase 3 interventional study of Immunoglobulin Intravenous (Human) in Immune Thrombocytopenic Purpura, sponsored by CSL Behring. Completed at 17 sites in 6 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-11-23.
Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Poland — 8 open to participants now, 10 under way, 6 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Poland.
Among the 38 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Poland, this one is the 25th largest by enrollment, is the only one that started in 2004, is one of 22 in phase 3, and was the 4th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →8 of the 38 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Poland are open now. Recruiting first, the newest first:
Sanofi · Sites in Poland, United States, Austria and 7 more countries
Ages 18+
argenx · Sites in Poland, France, Germany and 7 more countries
Ages 12–17
Takeda · Sites in Poland, United States, Australia and 12 more countries
Ages 18+
Eli Lilly and Company · Sites in Poland, United States, China and 7 more countries
Ages 18+
Takeda · Sites in Poland, United States, Australia and 15 more countries
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 12 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 23 · Phase 4 1
First in 2001; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is close to the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 69 across the 38 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 38 have an industry lead sponsor. The 10 most frequent:
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
CSL Limited has 3 studies filed under Purpura, Thrombocytopenic, Idiopathic — fewer than ten, so there is no comparison to draw.
3 of the studies in Purpura, Thrombocytopenic, Idiopathic with a site in Poland that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04812925Phase 3argenxA Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | 2027-10 |
| NCT07007962Phase 3SanofiStudy to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment | 2027-11-05 |
| NCT06371417Chugai PharmaceuticalPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 2027-03-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 38 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, tolerability and safety of IgPro10 in the treatment of patients with chronic immune thrombocytopenic purpura (ITP). The main efficacy parameter is the proportion of patients responding to treatment by an increase of platelet count to ≥ 50 x 10\^9/L.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Immunoglobulin Intravenous (Human)
A dose of 1 g IgG per kg body weight (bw) administered on two consecutive days resulting in the total treatment dosage of 2 g IgG per kg bw.
Also known as: Privigen, IgPro10
Platelet Response
The platelet response rate is defined as the percentage of subjects responding to treatment with an increase of platelet count from ≤ 20 x 10\^9/L to ≥ 50 x 10\^9/L within the specified time frame.
Time frame: 7 days
Regression of Hemorrhage (Skin)
Number of subjects with a decrease in the severity of bleeding from baseline (prior to first infusion) on at least one post-infusion assessment during the study period (e.g., a change from moderate to mild or a change from mild to none). Regression of hemorrhages was tabulated separately for the organ systems skin, oral cavity, genitourinary tract, nose, and internal.
Time frame: up to 29 days
Regression of Hemorrhage (Oral Cavity)
Number of subjects with a decrease in the severity of bleeding from baseline (prior to first infusion) on at least one post-infusion assessment during the study period (e.g., a change from moderate to mild or a change from mild to none). Regression of hemorrhages was tabulated separately for the organ systems skin, oral cavity, genitourinary tract, nose, and internal.
Time frame: 29 days
Regression of Hemorrhage (Genitourinary Tract)
Number of subjects with a decrease in the severity of bleeding from baseline (prior to first infusion) on at least one post-infusion assessment during the study period (e.g., a change from moderate to mild or a change from mild to none). Regression of hemorrhages was tabulated separately for the organ systems skin, oral cavity, genitourinary tract, nose, and internal.
Time frame: 29 days
Regression of Hemorrhage (Nose)
Number of subjects with a decrease in the severity of bleeding from baseline (prior to first infusion) on at least one post-infusion assessment during the study period (e.g., a change from moderate to mild or a change from mild to none). Regression of hemorrhages was tabulated separately for the organ systems skin, oral cavity, genitourinary tract, nose, and internal.
Time frame: 29 days
Regression of Hemorrhage (Internal)
Number of subjects with a decrease in the severity of bleeding from baseline (prior to first infusion) on at least one post-infusion assessment during the study period (e.g., a change from moderate to mild or a change from mild to none). Regression of hemorrhages was tabulated separately for the organ systems skin, oral cavity, genitourinary tract, nose, and internal.
Time frame: 29 days
Time to Platelet Response
Median time to reach a platelet count ≥ 50 x 10\^9/L.
Time frame: 29 days
Duration of Platelet Response
The number of days the platelet count remained ≥ 50 x 10\^9/L.
Time frame: up to 29 days
Maximum Platelet Level
Maximum absolute platelet count achieved over the duration of the study.
Time frame: 29 days
The study was performed as a multicenter study at 17 centers, 6 in Poland, 4 in the Ukraine, 4 in Russia, 1 in Germany, 1 in Italy and 1 in the United Kingdom (UK).
| Milestone | IgPro10 |
|---|---|
| Started | 57 |
| Completed | 55 |
| Not completed | 2 |
| Withdrew: Adverse event | 1 |
| Withdrew: Therapy failure | 1 |
The platelet response rate is defined as the percentage of subjects responding to treatment with an increase of platelet count from ≤ 20 x 10\^9/L to ≥ 50 x 10\^9/L within the specified time frame.
| Percent of participants | IgPro10 |
|---|---|
| Platelet Response | 80.7 (69.2 to 89.3) |
Number of subjects with a decrease in the severity of bleeding from baseline (prior to first infusion) on at least one post-infusion assessment during the study period (e.g., a change from moderate to mild or a change from mild to none). Regression of hemorrhages was tabulated separately for the organ systems skin, oral cavity, genitourinary tract, nose, and internal.
| participants | IgPro10 |
|---|---|
| Regression of Hemorrhage (Skin) | 31 |
Number of subjects with a decrease in the severity of bleeding from baseline (prior to first infusion) on at least one post-infusion assessment during the study period (e.g., a change from moderate to mild or a change from mild to none). Regression of hemorrhages was tabulated separately for the organ systems skin, oral cavity, genitourinary tract, nose, and internal.
| participants | IgPro10 |
|---|---|
| Regression of Hemorrhage (Oral Cavity) | 11 |
Number of subjects with a decrease in the severity of bleeding from baseline (prior to first infusion) on at least one post-infusion assessment during the study period (e.g., a change from moderate to mild or a change from mild to none). Regression of hemorrhages was tabulated separately for the organ systems skin, oral cavity, genitourinary tract, nose, and internal.
| participants | IgPro10 |
|---|---|
| Regression of Hemorrhage (Genitourinary Tract) | 7 |
Number of subjects with a decrease in the severity of bleeding from baseline (prior to first infusion) on at least one post-infusion assessment during the study period (e.g., a change from moderate to mild or a change from mild to none). Regression of hemorrhages was tabulated separately for the organ systems skin, oral cavity, genitourinary tract, nose, and internal.
No measurements were reported for this outcome.
Number of subjects with a decrease in the severity of bleeding from baseline (prior to first infusion) on at least one post-infusion assessment during the study period (e.g., a change from moderate to mild or a change from mild to none). Regression of hemorrhages was tabulated separately for the organ systems skin, oral cavity, genitourinary tract, nose, and internal.
No measurements were reported for this outcome.
Median time to reach a platelet count ≥ 50 x 10\^9/L.
| days | IgPro10 |
|---|---|
| Time to Platelet Response | 2.5 (1.0 to 5.0) |
The number of days the platelet count remained ≥ 50 x 10\^9/L.
| days | IgPro10 |
|---|---|
| Duration of Platelet Response | 15.4 (8.8 to 21.9) |
Maximum absolute platelet count achieved over the duration of the study.
| 10^9/L | IgPro10 |
|---|---|
| Maximum Platelet Level | 154 (10 to 1049) |
Collected over 28 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IgPro10 | — | 3/57 (5.3%) | 52/57 (91.2%) |
| Event | IgPro10 |
|---|---|
| DizzinessNervous system disorders | 1/57 |
| Meningitis asepticInfections and infestations | 1/57 |
| Sudden hearing lossEar and labyrinth disorders | 1/57 |
| Event | IgPro10 |
|---|---|
| HeadacheNervous system disorders | 38/57 |
| PyrexiaGeneral disorders | 14/57 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 11/57 |
| ContusionInjury, poisoning and procedural complications | 10/57 |
| PetechiaeSkin and subcutaneous tissue disorders | 7/57 |
| NauseaGastrointestinal disorders | 6/57 |
| Skin haemorrhageSkin and subcutaneous tissue disorders | 6/57 |
| VomitingGastrointestinal disorders | 6/57 |
| AnaemiaBlood and lymphatic system disorders | 6/57 |
| HyperthermiaGeneral disorders | 5/57 |
| Age Continuous(years) | IgPro10 |
|---|---|
| Mean | 38 ± 15 |
| Sex: Female, Male(Participants) | IgPro10 |
|---|---|
| Female | 34 |
| Male | 23 |
| Race/Ethnicity, Customized(participants) | IgPro10 |
|---|---|
| Caucasian | 57 |
| Weight(kg) | IgPro10 |
|---|---|
| Mean | 74.0 ± 15.5 |
| Body Mass Index(kg/m^2) | IgPro10 |
|---|---|
| Mean | 25.69 ± 4.56 |
The record gives a start of Dec 2004 and a completion of Feb 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins
Purpura, Thrombocytopenic, Idiopathic →